In a large retrospective study on 949 newly diagnosed DLBCL patients, lower levels of apoA1 correlated with lymphoma burden symptoms, advanced stage, increased rate of relapse, higher incidence of refractory disease, and shorter OS [31]. The gene discussed is APOA1; the disease is diffuse large B-cell lymphoma.